Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.8310
-0.1290 (-13.44%)
At close: May 9, 2025, 4:00 PM
0.8000
-0.0310 (-3.73%)
After-hours: May 9, 2025, 7:59 PM EDT
Pasithea Therapeutics Employees
Pasithea Therapeutics had 4 employees as of December 31, 2024. The number of employees decreased by 4 or -50.00% compared to the previous year.
Employees
4
Change (1Y)
-4
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$3,476,146
Market Cap
5.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | -4 | -50.00% |
| Dec 31, 2023 | 8 | -7 | -46.67% |
| Dec 31, 2022 | 15 | 10 | 200.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KTTA News
- 2 days ago - Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewsWire
- 3 days ago - Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - GlobeNewsWire
- 3 days ago - Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results - Benzinga
- 4 days ago - Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 - GlobeNewsWire
- 11 days ago - Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients - GlobeNewsWire
- 16 days ago - Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 4 weeks ago - Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewsWire